ResearcherFirst Affiliated Hospital of Nanchang UniversityNo recent work listed

Qing Han

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 7 November 2026

Known by name at one institution; no external author ID yet. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper

Papers 2

LDLRAD2 promotes pancreatic cancer progression through Akt/mTOR signaling pathway. Co-author DOI 10.1007/s12032-020-01451-0 ↗
Long noncoding RNA LINC00514 accelerates pancreatic cancer progression by acting as a ceRNA of miR-28-5p to upregulate Rap1b expression. Co-author DOI 10.1186/s13046-020-01660-5 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Junhe Li · 2 shared papers, 2020–2021 · strength 0.33
- Paper LDLRAD2 promotes pancreatic cancer progression through Akt/mTOR signaling pathway. DOI 10.1007/s12032-020-01451-0 ↗
- Paper Long noncoding RNA LINC00514 accelerates pancreatic cancer progression by acting as a ceRNA of miR-28-5p to upregulate … DOI 10.1186/s13046-020-01660-5 ↗
Zhiwang Song · 2 shared papers, 2020–2021 · strength 0.33
- Paper LDLRAD2 promotes pancreatic cancer progression through Akt/mTOR signaling pathway. DOI 10.1007/s12032-020-01451-0 ↗
- Paper Long noncoding RNA LINC00514 accelerates pancreatic cancer progression by acting as a ceRNA of miR-28-5p to upregulate … DOI 10.1186/s13046-020-01660-5 ↗
Jianping Xiong · 2 shared papers, 2020–2021 · strength 0.33
- Paper LDLRAD2 promotes pancreatic cancer progression through Akt/mTOR signaling pathway. DOI 10.1007/s12032-020-01451-0 ↗
- Paper Long noncoding RNA LINC00514 accelerates pancreatic cancer progression by acting as a ceRNA of miR-28-5p to upregulate … DOI 10.1186/s13046-020-01660-5 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.